TIAA CREF Investment Management’s Eledon Pharmaceuticals ELDN Stock Holding History

TIAA CREF Investment Management’s Portfolio ELDN Stock Details ELDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-226	Closed	-$31K	–	3144
2017 Q1	$31K	Hold	226	–	–	﹤0.01%	3071
2016 Q4	$36K	Sell	226 -5	-2%	-$958	﹤0.01%	3109
2016 Q3	$57	Hold	231	–	–	﹤0.01%	3099
2016 Q2	$206K	Buy	231 +21	+10%	+$23.2K	﹤0.01%	3088
2016 Q1	$191K	Hold	210	–	–	﹤0.01%	2982
2015 Q4	$297K	Hold	210	–	–	﹤0.01%	3017
2015 Q3	$352K	Buy	210 +90	+75%	+$185K	﹤0.01%	2973
2015 Q2	$259K	Sell	120 -10	-8%	-$19.3K	﹤0.01%	3090
2015 Q1	$238K	Hold	130	–	–	﹤0.01%	3042
2014 Q4	$311K	Buy	+130	New	+$309K	﹤0.01%	3054

Other funds holding ELDN

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LSC

Lyon Street Capital Sausalito, California $67M AUM

ECM

Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

TIAA CREF Investment Management's ELDN Position: Q2 2017 in Review

TIAA CREF Investment Management sold out of Eledon Pharmaceuticals (ELDN) in Q2 2017, closing a stake of 226 shares — an estimated $31K sold.

TIAA CREF Investment Management first reported a position in ELDN in Q4 2014 and held it in 10 quarters. The position peaked at $352K in Q3 2015. 19 funds tracked by Wall St. Rank hold ELDN as of Q2 2017.

TIAA CREF Investment Management reported no remaining Eledon Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
TIAA CREF Investment Management sold 226 Eledon Pharmaceuticals shares in Q2 2017, an estimated $31K.
TIAA CREF Investment Management first reported a position in Eledon Pharmaceuticals in Q4 2014 and held it in 10 quarters.
TIAA CREF Investment Management's Eledon Pharmaceuticals position peaked at $352K in Q3 2015.
19 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2017.

Based on TIAA CREF Investment Management's 13F filing for Q2 2017, filed 10 Aug 2017.